Antimicrobial resistance in community-acquired respiratory tract pathogens

Comprehensive Therapy

Volumn 25, Issue 1, 1999, Pages 20-29

  Lark, Rebecca L ^a   Chenoweth, Carol ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CILASTATIN; CLARITHROMYCIN; COTRIMOXAZOLE; GREPAFLOXACIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; DRUG MECHANISM; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; KLEBSIELLA PNEUMONIAE; MORAXELLA CATARRHALIS; NONHUMAN; PENICILLIN RESISTANCE; PNEUMONIA; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 0032921328     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02889831     Document Type: Article

References (83)

1. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med. 1995;333:1618-1624.
2. Marrie TJ. Community-acquired pneumonia. CID. 1994;18: 501-515.
3. Macfarlane JT, Finch RG, Ward MJ, Macrae AD. Hospital study of adult community-acquired pneumonia. Lancet. 1982;2:255-258.
4. th ed. New York: Churchill Livingstone; 1995:233-246.
5. th ed. New York: Churchill Livingstone; 1995:334-346.
6. Hooper DC. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. CID. 1998;27(suppl 1): S54-63.
7. Martinez-Martinez L, Garcia I, Ballesta S, Benedi VJ, Hernandez-Alles S, Pascual A. Energy-dependent accumulation of fluoroquinolones in quinolone-resistant Klebsiella pneumoniae strains. Antimicrob Agents Chemother. 1998;42:1850-1852.
8. th ed. New York: Churchill Livingstone; 1995:354-364.
9. Schmidt LH, Sesler CL. Development of resistance to penicillin by pneumococci. Proc Soc Exp Biol Med. 1943;52:353-357.
10. Kislak JW, Razavi LMB, Daly AK, Finland M. Susceptibility of pneumococci to nine antibiotics. Am J Med Sci. 1965;250: 261-8.
11. Hansman D, Bullen MM. A resistant pneumococcus [letter]. Lancet. 1967;2:264-265.
12. Klugman KP. Epidemiology, control and treatment of multiresistant pneumococci. Drugs. 1996;52(suppl 2):42-46.
13. Jacobs MR, Koornhof HJ, Robins-Browne RM, Stevenson CM, Vermaak ZA, Freiman I, et al. Emergence of multiply resistant pneumococci. N Engl J Med. 1978;299:735-740.
14. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 4th ed. NCCLS Document M7-A4. Wayne, PA: National Committee for Laboratory Standards, 1997.
15. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. CID. 1992;15:77-83.
16. Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995;333: 474-480.
17. Leggiadro RJ. The clinical impact of resistance in the management of pneumococcal disease. Infect Dis Clin North Am. 1997;11:867-874.
18. Murray BE. The growing threat of penicillin-resistant Streptococcus pneumoniae. Infect Dis Clin Prac. 1997;6(suppl 2): S21-S27.
19. Soares S, Kristinsson KG, Musser JM, Tomasz A. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s. J Infect Dis. 1993;168:158-163.
20. Spika JS, Facklam RR, Plikaytis BD, Oxtoby MJ, Pneumococcal Surveillance Working Group. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J Infect Dis. 1991;163:1273-1278.
21. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994;271:1831-1835.
22. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF, et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's pneumococcal sentinel surveillance system. J Infect Dis. 1996;174:986-993.
23. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrob Agents Chemother. 1994;38:2419-2425.
24. Hofmann J, Cetron MS, Farley MM, Baughman WS, Facklam RR, Elliott JA, Deaver KA, Breiman RF. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med. 1995;333:481-486.
25. Doern GV, Brueggemann A, Holley HP, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40:1208-1213.
26. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y, Laboratory Investigator Group. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis. 1997;29:249-257.
27. Linares J, Pallares R, Alonso T, Perez JL, Ayats J, Gudiol F, et al. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). CID. 1992;15:99-105.
28. Geslin P, Buu-Hoi A, Fremaux A, Acar JF. Antimicrobial resistance in Streptococcus pneumoniae: an epidemiological survey in France, 1970-1990. CID. 1992;15:95-98.
29. Marton A. Pneumococcal antimicrobial resistance: the problem in Hungary. CID. 1992;15:106-111.
30. Goldsmith CE, Moore JE, Murphy PG. Pneumococcal resistance in the UK. J Antimicrob Chemother. 1997;40(suppl A): 11-18.
31. Lee HJ, Park JY, Jang SH, Kim JH, Kim EC, Choi KW. High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea. CID. 1995;20:826-835.
32. Friedland IR, McCracken GH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med. 1994;331:377-382.
33. Plouffe JF, Franklin County Pneumonia Study Group. Levofloxacin in vitro activity against bacteremia isolates of Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 1996; 25:43-45.
34. Yagupsky P, Porat N, Fraser D, Prajgrod F, Merires M, McGee L, et al. Acquisition, carriage, and transmission of pneumococci with decreased antibiotic susceptibility in young children attending a day care facility in Southern Israel. J Infect Dis. 1998;177:1003-1012.
35. Reichler MR, Allphin AA, Breiman RF, Schreiber JR, Arnold JE, McDougal LK, et al. The spread of multiresistant Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis. 1992;166:1346-1353.
36. Guillernot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroedan F, et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998;279: 365-370.
37. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, Canueto-Quintero J, Sanchez-Porto A, Vergara-Campos A, et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. CID. 1997;24:1052-1059.
38. Bedos JP, Chevret S, Chastang C, Geslin P, Regnier B, French Cooperative Pneumococcus Study Group. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey. CID. 1996;22:63-72.
39. Nava JM, Bella F, Garau J, Lite J, Morera M, Marti C, et al. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. CID. 1994;19:884-890.
40. Kronenberger CB, Hoffman RE, Lezotte DC, Marine WM. Invasive penicillin-resistant pneumococcal infections: a prevalence and historical cohort study. Emerg Infect Dis. 1996;2:121-124.
41. Gress TW, Yingling KW, Stanek RJ, Mufson MA. Infection with Streptococcus pneumoniae moderately resistant to penicillin does not alter clinical outcome. Infect Dis Clin Prac. 1996;5:435-439.
42. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev. 1990;3:171-196.
43. File TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997;41:1965-1972.
44. Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxicillin-clavulanic acid and erythromycin. Eur Respir J. 1995;8:1999-2007.
45. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA. 1993;270:1826-1831.
46. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination coverage levels among persons aged > 65 years. MMWR. 1995;44:506-507, 513-515.
47. Fedson DS. Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996. CID. 1998;26: 1117-1123.
48. Chan CY, Molrine DC, George S, Tarbell NJ, Mauch P, Diller L, et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis. 1996;173: 256-258.
49. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science. 1994;265:1385-1387.
50. Leeper KV. Severe community-acquired pneumonia. Semin Respir Infect. 1996;11:96-108.
51. Farley MM, Stephens DS, Brachman PS, Harvey C, Smith JD, Wenger JD, et al. Invasive Haemophilus influenzae disease in adults. Ann Intern Med. 1992;116:806-812.
52. Tomeh MO, Starr SE, McGowan JE, Terry PM, Nahmias AJ. Ampicillin-resistant Haemophilus influenzae type b infection. JAMA. 1974;229:295-297.
53. Khan W, Ross S, Rodriguez W, Controni G, Saz AK. Haemophilus influenzae type b resistant to ampicillin: a report of two cases. JAMA. 1974;298-301.
54. Scriver SR, Walmsley SL, Kau CL, Hoban DJ, Brunton J, McGeer A, et al. Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their β-lactamases. Antimicrob Agents Chemother. 1994;38:1678-1680.
55. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med. 1995;99 (suppl 6B):3S-7S.
56. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 1990;34:2075-2080.
57. Doern GV, The Alexander Project Collaborative Group. Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: results of a 1992-93 Western Europe and USA collaborative surveillance study. J Antimicrob Chemother. 1996;38(suppl A):59-69.
58. Doern GV, Brueggemann AB, Pierce G, Holley HP, Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance survey. Antimicrob Agents Chemother. 1997;41: 292-297.
59. Berk SL, Kalbfleisch JH, The Alexander Project Collaborative Group. Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in Western Europe and in the USA. J Antimicrob Chemother. 1996;38(suppl A): 85-96.
60. Macfarlane J. An overview of community acquired pneumonia with lessons learned from the British Thoracic Society Study. Semin Respir Infect. 1994;9:153-165.
61. Wood GM, Johnson BC, McCormack JG. Moraxella catarrhalis: pathogenic significance in respiratory tract infections treated by community practitioners. CID. 1996;22: 632-636.
62. Malmvall BE, Brorsson JE, Johnsson J. In vitro sensitivity to penicillin V and β-lactamase production of Branhamella catarrhalis. J Antimicrob Chemother. 1977;3:374-375.
63. Percival A, Corkill JE, Rowlands J, Sykes RB. Pathogenicity of and β-lactamase production by Branhamella (Neisseria) catarrhalis. Lancet. 1977;2:1175.
64. Alvarez S, Jones M, Holtsclaw-Berk S, Guarderas J, Berk SL. In vitro susceptibilities and β-lactamase production of 53 clinical isolates of Branhamella catarrhalis. Antimicrob Agents Chemother. 1985;27:646-647.
65. Felmingham D, Robbins MJ, Tesfaslasie Y, Harding I, Shrimpton S, Gruneberg RN. Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season. J Antimicrob Chemother. 1998;41:411-415.
66. Feldman C, Ross S, Mahomed G, Omar J, Smith C. The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial chemotherapy. Respir Med. 1995;89:187-192.
67. Garb JL, Brown RB, Garb JR, Tuthill RW. Differences in etiology of pneumonias in nursing home and community patients. JAMA. 1978;240:2169-2172.
68. Levine SJ, White DA, Fels AOS. The incidence and significance of Staphylococcus aureus in respiratory cultures from patients infected with the human immunodeficiency virus. Am Rev Respir Dis. 1990;141:89-93.
69. Johnston BL. Methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia: a critical review. Semin Respir Infect. 1994;9:199-206.
70. Maranan MC, Moreira B, Boyle-Vavra S, Daum RS. Antimicrobial resistance in Staphylococci: epidemiology, molecular mechanisms, and clinical relevance. Infect Dis Clin North Am. 1997;11:813-849.
71. Panlilio AL, Culver DH, Gaynes RP, Banerjee S, Henderson TS, Tolson JS, et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-586.
72. Moreno F, Crisp C, Jorgensen JH, Patterson JE. Methicillin-resistant Staphylococcus aureus as a community organism. CID. 1995;21:1308-1312.
73. Archibald L, Phillips L, Monnet D, McGowan JE, Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. CID. 1997;24:211-215.
74. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998;279:593-598.
75. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis. 1994;13:50-55.
76. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis. 1991;163:1279-1285.
77. Bauernfeind A, The Alexander Project Collaborative Group. Antibiotic susceptibility patterns of respiratory isolates of Klebsiella pneumoniae in Europe and the USA in 1992 and 1993. J Antimicrob Chemother. 1996;38(suppl A):107-115.
78. Sanders CC, Sanders WE. β-lactam resistance in gram-negative bacteria: global trends and clinical impact. CID. 1992; 15:824-839.
79. Pitout JDD, Sanders CC, Sanders WE. Antimicrobial resistance with focus on β-lactam resistance in gram-negative bacilli. Am J Med. 1997;103:51-59.
80. Jacoby GA. Extended-spectrum β-lactamases and other enzymes providing resistance to oxyimino-β-lactams. Infect Dis Clin North Am. 1997;11:875-887.
81. Jones RN, Pfaller MA, Doern GV, Erwin ME, Hollis RJ. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Diagn Microbiol Infect Dis. 1998;30:215-228.
82. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. CID. 1995;20:557-560.
83. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994;38:681-687.